click
Contact

Tag: IND-enabling Toxicity Studies

Contact

Search Medicilon

Preclinical CRO

World’s First Phase III Positive B7-H3 ADC: Medicilon Congratulates MediLink Therapeutics on NDA Acceptance of Icontamrotamab

Read more
Preclinical CRO

Medicilon Webinar | IND-enabling Toxicity Studies, CTD Documentation and Translational Cardiac Risk Assessment

Read more
Preclinical CRO

Medicilon Stands Out at ASMS 2026: Only CRO Selected for Bioanalysis Zone’s ‘Pick of the Posters’

Read more

Contact Medicilon

Name(Required)
Address(Required)